IMMUNIC, Inc. recently reported key progress in the Phase 3 ENSURE trial for vidofludimus calcium (IMU-838), its lead oral small molecule targeting relapsing multiple sclerosis (RMS), reinforcing its differentiated therapeutic profile in autoimmune diseases. A reverse stock split approved in April 2026 aims to address Nasdaq listing compliance and improve trading liquidity, amid ongoing financing challenges highlighted by persistent operating losses and a cash runway constrained to under twelve months without further capital raises. The company’s robust intellectual property, supported by encouraging Phase 2 data on neuroprotective and anti-inflammatory effects, underpins its competitive moat, although developmental and regulatory risks remain substantial ahead of anticipated late-stage trial readouts and subsequent regulatory submissions.